Related Experiment Video
Updated: Apr 9, 2026
Improved Generation of Induced Cardiomyocytes Using a Polycistronic Construct Expressing Optimal Ratio of Gata4, Mef2c and Tbx5
Published on: November 13, 2015
Generation of two induced pluripotent stem cell lines from hypertrophic cardiomyopathy patients carrying MYBPC3
Catherine A Wu1, Matthew A Wu1, Shane R Zhao2
1Stanford Cardiovascular Institute, Stanford University, Stanford, CA 94305, USA.
Insights
Induced pluripotent stem cells (iPSCs) were created from hypertrophic cardiomyopathy (HCM) patients with MYBPC3 mutations. These patient-specific iPSC lines offer a new model for studying inherited cardiac disease mechanisms and therapies.
Area of Science:
- Cardiovascular Medicine
- Stem Cell Biology
- Genetics
Background:
- Hypertrophic cardiomyopathy (HCM) is a common inherited heart condition.
- Mutations in the MYBPC3 gene are a primary cause of HCM.
- Understanding HCM pathogenesis requires effective disease models.
Purpose of the Study:
- To generate patient-specific induced pluripotent stem cell (iPSC) lines from individuals with MYBPC3 mutations.
- To establish a cellular model for studying MYBPC3-associated HCM.
- To facilitate research into the mechanisms and potential therapies for inherited cardiac diseases.
Main Methods:
- Collected peripheral blood mononuclear cells from HCM patients with specific MYBPC3 mutations.
- Reprogrammed cells into induced pluripotent stem cells (iPSCs).
- Characterized iPSC lines for pluripotency markers, karyotype stability, and differentiation potential.
Main Results:
- Successfully generated two distinct patient-specific iPSC lines carrying MYBPC3 mutations (c.2490dupT and c.1800delA).
- Confirmed normal cell morphology and stable karyotypes in both iPSC lines.
- Demonstrated robust expression of pluripotency markers and trilineage differentiation capacity.
Conclusions:
- Patient-derived iPSC lines are a viable tool for modeling MYBPC3-associated HCM.
- These iPSC models enable further investigation into the molecular mechanisms of HCM.
- The developed cell lines support the exploration of novel therapeutic strategies for inherited cardiac disorders.
Abstract:
Hypertrophic cardiomyopathy (HCM) is a prevalent inherited cardiac disorder characterized by left ventricular hypertrophy and contractile dysfunction. Mutations in sarcomeric genes, particularly cardiac myosin-binding protein C (MYBPC3), are a leading cause of HCM. Here, we generated two induced pluripotent stem cell (iPSC) lines from peripheral blood mononuclear cells of patients carrying distinct MYBPC3 mutations (c.2490dupT and c.1800delA). Both lines displayed normal morphology, stable karyotypes, robust expression of pluripotency markers, and trilineage differentiation potential. These patient-specific iPSC lines provide a valuable platform for modeling MYBPC3-associated HCM and enable mechanistic and therapeutic studies of inherited cardiac disease.
